Usefulness Of Quantitative Assessment of Junb Gene Expression as a Marker for Monitoring Chronic Myeloid Leukemia Patients Undergoing Imatinib Therapy

Abstract

JunB is a component of the activator protein 1 transcription factors and has been identified to be important in hematopoiesis. Transgenic mice lacking JunB expression develop myeloproliferative disease resembling human chronic myeloid leukemia (CML). JunB expression was significantly decreased in CML patients. We used real-time quantitative reverse transcription-polymerase chain reaction analysis to monitor both JunB and BCR-ABL expression during imatinib therapy. Nineteen patients were evaluated every 2 to 4 weeks, and their levels of JunB expression before therapy were significantly decreased compared with those of healthy individuals. After imatinib therapy, an increase in JunB expression was found in 5 patients, all of whom achieved a complete cytogenetic response (CCR) and molecular response (MR), with a decrease in BCR-ABL expression. JunB expression decreased to a very low level in 2 patients, both of whom showed progression to blast crisis. Variable JunB expression was found in the other 12 patients, and their outcomes were mostly driven by BCR-ABL levels. The patients with an increase in JunB expression were statistically more likely to achieve a major cytogenetic response (P = .045), CCR (P = .033), and MR (P = .033) than the group with no increase in JunB expression, and a durable response was observed. This study revealed that an increase in JunB expression is a good prognostic marker for predicting clinical response in CML patients treated with imatinib when such data are combined with an evaluation of BCR-ABL expression.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene. 2001;20:2378–2389.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Deng T, Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev. 1993;7:479–490.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Hsu JC, Cressman DE, Taub R. Promoter-specific trans-activation and inhibition mediated by JunB. Cancer Res. 1993;53:3789–3794.

    CAS  PubMed  Google Scholar 

  4. 4.

    Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000;19:2056–2068.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Passegué E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression. EMBO J.2000;19:2969–2979.

    Article  PubMed  Google Scholar 

  6. 6.

    Szabowski A, Maas-Szabowski N, Andrecht S, et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell. 2000;103:745–755.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999;13:607–619.

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell. 2000;103:897–907.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Passegué E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell. 2001;104:21–32.

    Article  PubMed  Google Scholar 

  10. 10.

    Szremska AP, Kenner L, Weisz E, et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood. 2003;102:4159–4165.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2003;101:1513–1519.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J. 2002;21:4104–4113.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Yang MY, Liu TC, Chang JG, Lin PM, Lin SF. JunB gene expression inactivated by methylation in chronic myelogenous leukemia. Blood. 2003;101:3205–3211.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med. 2002;346:683–693.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

    Article  PubMed  Google Scholar 

  16. 16.

    Kantarjian H, Sawyers C, Hochhaus A. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Talpaz M, Silver RT, Druker BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: result of a phase 2 study. Blood. 2002;99:1928–1937.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Sawyers CL, Hochhaus A, Feldman E. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–3539.

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αlpha. Leukemia. 2002;16:1579–1583.

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 2002;118:771–777.

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;35:1423–1432.

    Article  Google Scholar 

  22. 22.

    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880.

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of ±1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641–1650.

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hemato-poietic cells: a transgenic study for blast crisis of human CML. Blood. 2000;95:1144–1150.

    CAS  PubMed  Google Scholar 

  26. 26.

    Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay. Leukemia. 1999;13:957–964.

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia. 1999;13:1383–1389.

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–1464.

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–3356.

    CAS  PubMed  Google Scholar 

  30. 30.

    Barnes DJ, Melo JV. Management of chronic myeloid leukemia: targets for molecular therapy. Semin Hematol. 2003;40:34–49.

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746–11750.

    Article  CAS  PubMed  Google Scholar 

  32. 32.

    Burgess GS, Williamson EA, Cripe LD, et al. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998;92:2450–2460.

    CAS  PubMed  Google Scholar 

  33. 33.

    Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–4022.

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;98:2039–2342.

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol. 2003;40(suppl 2):98–103.

    PubMed  Google Scholar 

  36. 36.

    Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850–858.

    Article  CAS  PubMed  Google Scholar 

  37. 37.

    Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160–166.

    CAS  PubMed  Google Scholar 

  38. 38.

    Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol. 2003;40:62–68.

    CAS  PubMed  Google Scholar 

  39. 39.

    Passegué E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004;119:431–443.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Yi-Chang Liu or Hui-Hua Hsiao or Jan-Gowth Chang or Ming-Yu Yang or Ta-Chih Liu or Chao-Song Chang or Shih-Bin Tseng or Huei-Jen Tsai or Sheng-Fung Lin.

About this article

Cite this article

Liu, Y., Hsiao, H., Chang, J. et al. Usefulness Of Quantitative Assessment of Junb Gene Expression as a Marker for Monitoring Chronic Myeloid Leukemia Patients Undergoing Imatinib Therapy. Int J Hematol 84, 425–431 (2006). https://doi.org/10.1532/IJH97.A10514

Download citation

Key words

  • JunB
  • Imatinib mesylate
  • BCR-ABL
  • Real-time quantitative RT-PCR
  • Chronic myeloid leukemia